Video

What To Know About Aducanumab and Slowing the Progression of Alzheimer Disease

Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.

Pharmacy Times spoke to Dr.Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Burned out pharmacy resident -- Image credit: Anela Ramba/peopleimages.com | stock.adobe.com
June 6th 2025

Resident Mental Health Matters

Brianne Perry, PharmD
Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development
August 23rd 2024

Pharmacy Focus: Alzheimer Drug Pipeline Expands, Promising Therapies in Development

Ashley Gallagher, Editor
AI-generated depiction of neurons within the brain -- Image credit: Gadda | stock.adobe.com
May 27th 2025

WEHI-3773 May Be Leveraged to Develop Therapeutic Strategies for Neurodegenerative Conditions

Gillian McGovern, Associate Editor
Depiction of plaque build up on neurons within brain -- image credit: Dr_Microbe | stock.adobe.com
May 19th 2025

FDA Grants Market Clearance to Diagnostic Blood Test for Alzheimer Disease

Gillian McGovern, Associate Editor